Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: Involvement of the RhoA/Rho kinase pathway

FEBS Letters

Volumn 583, Issue 18, 2009, Pages 2997-3003

  Ye, Yang ^a   Hu, Shen Jiang ^a,b   Li, Liang ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Immunology Division   (China)

Author keywords

Angiotensin II; Cardiomyocytes; Farnesylpyrophosphate synthase; Geranylgeranylation; RhoA

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALENDRONIC ACID; ANGIOTENSIN II; EXOENZYME C3; GERANYLGERANIOL; GERANYLTRANSFERASE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART MUSCLE CELL; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ALENDRONATE; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; DIMETHYLALLYLTRANSTRANSFERASE; HYPERTROPHY; MYOCYTES, CARDIAC; PRENYLATION; RATS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

RATTUS;

EID: 69949140722     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.08.034     Document Type: Article

References (35)

1. Baker K.M., Booz G.W., and Dostal D.E. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu. Rev. Physiol. 54 (1992) 227-241
2. Chien K.R., Knowlton K.U., Zhu H., and Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5 (1991) 3037-3046
3. Liang F., and Gardner D.G. Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes. J. Biol. Chem. 273 (1998) 14612-14619
4. Komuro I. Molecular mechanism of cardiac hypertrophy and development. Jpn. Circ. J. 65 (2001) 353-358
5. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52 (2000) 11-34
6. Aoki H., Izumo S., and Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ. Res. 82 (1998) 666-776
7. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 93 (2003) 767-775
8. Morikawa-Futamatsu K., Adachi S., Maejima Y., Tamamori-Adachi M., Suzuki J., Kitajima S., et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci. 79 (2006) 1380-1390
9. Aikawa R., Komuro I., Nagai R., and Yazaki Y. Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol. Cell. Biochem. 212 (2000) 177-182
10. Scheffzek K., Stephan I., Jensen O.N., Illenberge D., and Gierschik P. The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI. Nat. Struct. Biol. 7 (2000) 122-126
11. Gelb M.H. Protein prenylation, et cetera: signal transduction in two dimensions. Science 275 (1997) 1750-1751
12. Moomaw J.F., and Casey P.J. Mammalian protein geranylgeranyl transferase. Subunit composition and metal requirements. J. Biol. Chem. 267 (1992) 17438-17443
13. Bishop A.L., and Hall A. Rho GTPases and their effector proteins. Biochem. J. 348 (2000) 241-255
14. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesylpyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264 (1999) 108-111
15. Kavanagh K.L., Guo K., Dunford J.E., and Wu X. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. PNAS 103 (2006) 7829-7834
16. Casey P.J. Mechanisms of protein prenylation and role in G protein function. Biochem. Soc. Trans. 23 (1995) 161-166
17. Casey P.J. Protein lipidation in cell signaling. Science 268 (1995) 221-225
18. Takai Y., Sasaki T., and Matozaki T. Small GTP-binding proteins. Physiol. Rev. 81 (2001) 153-208
19. Lavandero S., Foncea R., Pérez V., and Sapag-Hagar M. Effect of inhibitors of signal transduction on IGF-1-induced protein synthesis associated with hypertrophy in cultured neonatal rat ventricular myocytes. FEBS Lett. 422 (1998) 193-196
20. Simpson P., and Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Circ. Res. 50 (1982) 101-116
21. Yamamoto K., Ohki R., Lee R.T., Ikeda U., and Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
22. Nlend M.C., Schmid A., Sutto Z., Ransford G.A., Conner G.E., Fregien N., et al. Calcium-mediated, purinergic stimulation and polarized localization of calcium-sensitive adenylyl cyclase isoforms in human airway epithelia. FEBS Lett. 581 (2007) 3241-3246
23. Peinnequin A., Mouret C., Birot O., Alonso A., Mathieu J., Clarençon D., et al. Ratpro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. BMC Immunol. 5 (2004) 3
24. Aelst L., and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 11 (1997) 2295-2322
25. 2+ signaling. Atherosclerosis 193 (2007) 44-54
26. Hayashi M., Sakata M., Takeda T., Tahara M., Yamamoto T., Minekawa R., et al. Hypoxia upregulates hypoxia-inducible factor-1alpha expression through RhoA activation in trophoblast cells. J. Clin. Endocrinol. Metab. 90 (2005) 1712-1719
27. Woods A., Wang G., and Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J. Biol. Chem. 280 (2005) 11626-11634
28. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373 (2000) 231-241
29. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
30. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. 96 (1999) 133-138
31. Sawaka K., Morishige K., Tahara M., Kawagishi R., Ikebuchi Y., Tasaka K., and Murata Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res. 6 (2002) 6015-6020
32. Hashimoto K., Morishige K.-I., Sawada K., Tahara M., Shimizu S., Ogata S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun. 354 (2007) 478-484
33. Laufs U., and Liao J.K. Targeting Rho in cardiovascular disease. Circ. Res. 87 (2000) 526-528
34. Laufs U., Kilter H., Konkol C., Wassmann S., Böhm M., and Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc. Res. 53 (2002) 911-920
35. Wang Y.X., da Cunha V., Martin-McNulty B., Vincelette J., Li W., Choy D.F., et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur. J. Pharmacol. 512 (2005) 215-222